Please select the option that best describes you:
How would you treat a younger patient with relapsed mantle cell lymphoma after treatment with hyperCVAD?
How about if disease is found in the CSF?
Answer from: Medical Oncologist at Academic Institution
In front line therapy for MCL patients, induction followed by ASCT should be the standard of care followed by rituximab maintenance and follow up for MRD.In relapsed MCL, after anthracycline and cytrabine containing therapy, BTK inhibitors appear to be the most affective agents.Results of a pooled a...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Agee with @Ahmed Sawas. The only confounder being that in some cases patients treated with R-HyperCVAD do not proceed to stem cell transplantation in first remission. In those cases you could consider salvage with another chemotherapeutic again (R-DHAP/DHAOx) to induce remission and consolidat...